BDTX News and Press, Black Diamond Therapeutics Inc. From 01/12/24

2024-01-12 17:21:02 ET Summary Black Diamond Therapeutics is a precision oncology company targeting genetically defined cancers with its Masterkey approach. Besides NSCLC, BDTX also produced positive early data in recurrent GBM, a notoriously hard-to-treat disease. The company...

FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track Designation granted for BDTX-1535 as second-line treatment for EGFR mutant/C797S NSCLC BDTX-1535 Phase 2 results for 2L/3L patients with EGFR muta...

Initial results show promising clinical activity in heavily pretreated patients 22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and 5 patients longer than 4 months 19 patients with measurable disease by RANO criter...

2023-11-07 08:42:51 ET Carbon Revolution Public  ( CREV ) +46% . Transmedics Group  ( TMDX ) +42% Q3 earnings call release Olaplex Holdings  ( OLPX ) +29% Q3 earnings call release Unisys  ( UIS ) +24% Q3 earnings call release ...

Black Diamond Therapeutics Inc. (BDTX) is expected to report $-0.49 for Q3 2023

2023-11-06 11:48:10 ET More on Black Diamond Therapeutics Black Diamond's BDTX-1535: A Brainy Bet In Cancer Therapy Seeking Alpha’s Quant Rating on Black Diamond Therapeutics Historical earnings data for Black Diamond Therapeutics Financial information...

Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three active once daily doses of 100mg, 200mg and 300mg Initial NSCLC exp...

2023-10-12 08:31:24 ET Summary Black Diamond Therapeutics exhibits prudent financials and a stable short-term outlook, but curtailed R&D spending could slow clinical progress. The company's lead candidate, BDTX-1535, shows promise in NSCLC and potential in treating glioblastom...

2023-10-05 17:23:44 ET Gainers: nCino ( NASDAQ: NCNO ) +8% . TPI Composites ( TPIC ) +6% . SCYNEXIS ( SCYX ) +5% . Sutro Biopharma ( STRO ) +5% . Black Diamond Therapeutics ( BDTX ) +4% . Losers: SomaLogic ( SLGC ...

CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced fort...